Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Overweight or Obese Subjects
NCT06054698Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Oct 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06054698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054698.